GSK (GSK LN) Q4 (GBP): Revenue 8.1bln (exp. 8.05bln), Core EPS 0.23 (exp. 0.43). FY24: Sales 31.38bln (exp. 31.2bln), adj. EPS 1.59 (exp. 1.55), adj. Operating Profit 9.15bln (exp. 8.3bln). GBP 2bln buyback over the next 12-months.

FY Outlook

Long Term Outlook (2031)

Analysis details (07:05)

05 Feb 2025 - 07:00- EquitiesImportant- Source: Newswires

GSK.LNUnited KingdomGlaxoSmithKline PLCGSKCore CorpPharmaceuticals (Group)Pharmaceuticals, Biotechnology & Life SciencesGSK plcPharmaceuticalsFTSE 100 IndexEquitiesEuropeEU SessionEU SessionImportantImportantGBP

Subscribe Now to Newsquawk

Click here for a 1 week free trial

Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: